SWM
ALNY icon

Spire Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Spire Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5K Buy
201
+1
+0.5% +$302 ﹤0.01% 1124
2026
Q1 		$66.2K Sell
200
-2
-1% -$681 ﹤0.01% 1094
2025
Q4 		$80.3K Sell
202
-5
-2% -$2.21K ﹤0.01% 1050
2025
Q3 		$94.3K Buy
207
+2
+1% +$814 ﹤0.01% 1006
2025
Q2 		$66.8K Buy
205
+1
+0.5% +$277 ﹤0.01% 1110
2025
Q1 		$55.1K Sell
204
-1
-0.5% -$257 ﹤0.01% 1241
2024
Q4 		$48.3K Sell
205
-175
-46% -$46K ﹤0.01% 1298
2024
Q3 		$105K Buy
380
+3
+0.8% +$781 ﹤0.01% 903
2024
Q2 		$91.6K Sell
377
-206
-35% -$32.5K ﹤0.01% 917
2024
Q1 		$87.1K Buy
583
+3
+0.5% +$500 ﹤0.01% 1030
2023
Q4 		$107K Hold
580
– – ﹤0.01% 980
2023
Q3 		$103K Sell
580
-1
-0.2% -$191 ﹤0.01% 942
2023
Q2 		$110K Sell
581
-315
-35% -$62.5K ﹤0.01% 941
2023
Q1 		$179K Buy
896
+224
+33% +$47.1K 0.01% 765
2022
Q4 		$160K Sell
672
-13
-2% -$2.77K 0.01% 606
2022
Q3 		$137K Sell
685
-247
-27% -$47.1K 0.01% 616
2022
Q2 		$136K Sell
932
-418
-31% -$59.3K 0.01% 908
2022
Q1 		$221K Buy
1,350
+882
+188% +$134K 0.01% 847
2021
Q4 		$81K Buy
468
+9
+2% +$1.67K ﹤0.01% 1497
2021
Q3 		$87K Hold
459
– – ﹤0.01% 1243
2021
Q2 		$78K Buy
459
+22
+5% +$3.22K ﹤0.01% 1296
2021
Q1 		$62K Buy
+437
New +$65.8K ﹤0.01% 1616

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spire Wealth Management's ALNY Position: Q2 2026 in Review

Spire Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.5% in Q2 2026, buying an estimated $302 and bringing the position to 201 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1124.

Spire Wealth Management first reported a position in ALNY in Q1 2021 and has held it in 22 quarters since. The position peaked at $221K in Q1 2022. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Spire Wealth Management held 201 shares of Alnylam Pharmaceuticals worth $60.5K as of Q2 2026.
  • Spire Wealth Management bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #1124 holding.
  • Spire Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Spire Wealth Management's Alnylam Pharmaceuticals position peaked at $221K in Q1 2022.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.